Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 10Plasma cell 4Classical hematology 3Breast 3Other neoplasm 2Myeloid 2Genitourinary 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1Gynecologic 1Dermatologic 1CNS 1

Conditions

Prostatic Neoplasms 2

Interventions

Prednisone 122Docetaxel 118enzalutamide 101pembrolizumab 96Sunitinib 86Leuprolide 84Abiraterone Acetate 83Nivolumab 78Gemcitabine 76bicalutamide 54Radiotherapy 54Goserelin 54Bevacizumab 54Cisplatin 52Magnetic Resonance Spectroscopy 49Everolimus 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 46Sorafenib 40Carboplatin 40Paclitaxel 37Radiosurgery 36atezolizumab 35abiraterone 33pazopanib 32cabozantinib 32Ipilimumab 32Axitinib 30Cyclophosphamide 29Androgen Antagonists 29Radiation 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Aspirin × Genitourinary × Clear all
NCT03103152 2023-03-29

PROVENT

Queen Mary University of London

Phase 2/3 Completed
104 enrolled 14 charts
Genitourinary

Prostatic Neoplasms

NCT02420652 2023-02-08

PRIMA

Rutgers, The State University of New Jersey

Phase 2 Terminated
27 enrolled 6 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡